ASH 2023 | ASH 2023: what to look forward to in the MPN space
Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL, shares the aspects of the upcoming American Society of Hematology (ASH) 2023 meeting that he is most excited for in the space of myeloproliferative neoplasms (MPNs), including the results of two large Phase III trials of combination therapies versus ruxolitinib. Dr Kuykendall looks forward to lively debates and discussions with fellow experts on the newly presented data in this field. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Celgene/BMS, Cogent, Incyte, Abbvie, Imago, Novartis, PharmaEssentia, CTI Biopharma, MorphoSys, GSK, Karyopharm
Research Funding: MorphoSys, BMS, Protagonist Therapeutics, Janssen
Advisory Board: Dark Blue Therapeutics
